Live tape
Top 8, mentions 7d7,543META2,264 mentions▲ +0.06GOOGL1,512 mentions▲ +0.02NVDA805 mentions▲ +0.09MUSE666 mentions▲ +0.07MSFT606 mentions▲ +0.06SPY572 mentions▲ +0.05QQQ564 mentions▲ +0.08TSLA554 mentions▲ +0.06

Equity · Healthcare

PRAX

Praxis Precision Medicines, Inc. · NasdaqGS

$311 +0.65% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Sep 17, 2026
Price · Chart
Our own end-of-day closes 37 sessions
$400 $300 30 Jun 17 Sep

The line runs $335.29 on 30 June through $311 on 17 September, on a scale from $300 to $400. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of PRAX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 37 sessions over that window: $335.29 on 30 June 2026 through $311 on 17 September 2026.

Market cap $8.7B
52-week range $37.71 – $386
Avg volume 29.6K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Sep 17, 2026

PRAX insider trades

SEC Form 4 · last 90 days · newest Form 4 filing 8 Jul 2026
Open-market buys 0
Open-market sells 0
Non-trade filings 1

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Jul 2026 Souza Marcio Chief Executive Officer Gift 23,121

PRAX reported financials

SEC EDGAR XBRL

PRAX reported revenue of $0 for the fiscal year ended 31 Dec 2025. Net income over the same period was −$303.3M.

Figure Reported Period
Revenue $0 31 Dec 2025 fiscal year
Net income −$303.3M 31 Dec 2025 fiscal year
Diluted EPS −$13.48 31 Dec 2025 fiscal year
Total assets $1.4B 30 Jun 2026 at period end
Total equity $1.3B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

PRAX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-2.87 —
31 Mar 2026 Q1 2026 $-3.20 —
31 Dec 2025 FY 2025 $-13.48 —
30 Sep 2025 Q3 2025 $-3.36 —
30 Jun 2025 Q2 2025 $-3.31 —
31 Mar 2025 Q1 2025 $-3.29 —
31 Dec 2024 FY 2024 $-10.21 $9M
30 Sep 2024 Q3 2024 $-2.75 $0M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

PRAX institutional holders

SEC Form 13F

10 of the 45 institutional funds we track reported a PRAX position for the quarter ended 30 Jun 2026 — a combined $671.6M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 1,753,198 $587.0M
Marshall Wace Added +203.5% shares 137,008 $45.9M
AQR Capital Management Held (±25%) −0.4% shares 58,446 $19.6M
Man Group Added +567.0% shares 21,164 $7.1M
Two Sigma Investments Held (±25%) +6.6% shares 18,758 $6.3M
Citadel Advisors New position 7,331 $2.5M
D. E. Shaw & Co. New position 5,140 $1.7M
Tudor Investment Corp New position 2,183 $731K
Balyasny Asset Management New position 1,880 $629K
Millennium Management Trimmed −74.0% shares 995 $333K

Source: SEC EDGAR 13F filings

PRAX fails-to-deliver

SEC CNS data

On 27 Aug 2026, 437 shares of PRAX failed to deliver (about $165K).

Settlement date Shares failed Notional % of shares out
27 Aug 2026 437 $165K 0.002%
25 Aug 2026 49 $18K <0.001%

Source: SEC fails-to-deliver (CNS) data